An Observational Study of Adherence to Anastrozole in Early Breast Cancer Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

259 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-08-31

Study Completion Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to describe adherence to anastrozole treatment current practice: cases where anastrozole treatment was halted ( timescale and causes) and estimate the proportion of postmenopausal women with early breast cancer who continue anastrozole therapy after one year follow-up.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer

NCT00638391

Breast Cancer

COMPLETED

Patient's Anastrozole Compliance to Therapy Programme

NCT00555867

Breast Cancer

TERMINATED

The Performance of Patient Support Program in Early Stage Breast Cancer

NCT00769080

Breast Cancer

COMPLETED

Secondary Adjuvant Long Term Study With Arimidex

NCT00295620

Breast Cancer

COMPLETED PHASE3

Retrospective Observational Trial on Reasons for Withdraw of Adjuvant Tamoxifen in Breast Cancer Patients

NCT00727883

Breast Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Postmenopausal woman with early breast cancer who are prescribed with anastrozole as adjuvant endocrine therapy under the routine clinical practice.
* Histologically or cytologically proven to be HR+(ER or PR +)
* No other concomitant endocrine therapy such as estrogen therapy or selective estrogen receptor modulators
* Provision of written informed consent

Exclusion Criteria

* Recurrence of breast cancer
* Known hypersensitivity to anastrozole or to any of its excipients
* Any severe concomitant condition which makes it undesirable for the patient to participate in the trial or which would jeopardize adherence with the trial protocol: Amenorrhea\<12 months and a intact uterus; Previous inclusion in the present study; Participation in a other clinical study during the last 30 days·
* Women who does not agreed to participate the program

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No